Typhoid Vaccine Acceleration Consortium (TyVAC)
The Typhoid Vaccine Acceleration Consortium (TyVAC) aims to accelerate the use of typhoid conjugate vaccine (TCV) in endemic settings and support country decision-making. We employ a complementary suite of activities to optimize the use – and ultimately public health impact – of TCVs while simultaneously supporting the long-term sustainability of TCV programs and collaborative partnerships.
Typhoid, a serious enteric fever caused by Salmonella Typhi, is spread through contaminated food and water. While largely eliminated in industrialized countries, typhoid continues to be a substantial public health issue in Asia, sub-Saharan Africa, and parts of Latin America and the Middle East.
The Global Burden of Disease estimates typhoid caused more than 9 million infections and more than 110,000 deaths globally in 2019, with young children and adolescents aged 2 to 15 years disproportionately impacted. Though treatable with antibiotics, the number of cases resistant to available antibiotics is increasing.
There are currently two TCVs, Typbar TCV® and TYPHIBEV®, approved and recommended for use by the World Health Organization. A single dose of TCV is safe, well-tolerated, and efficacious for at least four years, including in children younger than 2 years of age.
Engage with countries and local partners, provide assistance while fostering country ownership, strengthen local capacity, support decision-making, and enhance collaboration.
Coordinate with the typhoid community, maintain momentum and attention on typhoid as a global health priority, and ensure widespread and sustainable TCV introductions.
Generate new evidence related to typhoid disease burden, antimicrobial resistance, cost-effectiveness/cost-of-illness, and regional data on TCVs.
Advocate with partners for an integrated approach that includes vaccines in combination with improved water, sanitation, and hygiene (WASH).
Project Director, Kathleen Neuzil, is the Myron M. Levine Professor in Vaccinology, Professor of Medicine and Pediatrics, and the Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine. She is an internationally recognized research scientist and advocate in the field of vaccinology and has led TyVAC since its inception in 2017. She has more than 300 scientific publications on vaccines and infectious diseases. Dr. Neuzil is a member of the World Health Organization Strategic Advisory Group of Experts on Immunization and the prestigious National Academy of Medicine.
- TCV protects for over 4 years!
- When the dam was spilled: the reality of typhoid risk
- Typhoid burden, challenges, and the promise of typhoid conjugate vaccines
- Potential to estimate typhoid burden through serosurvey
- The typhoid community gathers in Rwanda to collaborate, share data, and maintain momentum for typhoid control
- Environmental sampling detects typhoid bacteria in Nepal
- A lack of diagnostic tools contributes to drug-resistant typhoid
- Drug resistant typhoid: what does it all mean?
- Typhoid - what's surgery got to do with it?
- What the spread of extensively drug-resistant Salmonella Typhi tells us about future outbreaks
- Phone: 410-706-5328
- Email: TyVAC@som.umaryland.edu
Visit the Take on Typhoid website for additional information and to sign up for our newsletter!